PRAC recommends measures to minimise the risk of serious side effects with medicines containing pseudoephedrine
The European PRAC has recommended new measures for these medicines to minimise the risks of posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome, including avoiding use in those with severe or uncontrolled hypertension, among others.
Source:
European Medicines Agency
SPS commentary:
The MHRA announced earlier this year that they are “reviewing available evidence" on potentially serious side effects linked to medicines containing pseudoephedrine, following an announcement from the European Medicines Agency on a similar review. The results of this review and any subsequent recommended changes to the marketing authorisations for these medicines in the UK are awaited.